Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

7(70.0%)

N/A

3(30.0%)

10Total

Phase 2(7)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03861728Not ApplicableTerminated

Viral Conjunctivitis Treatment Study

Role: collaborator

NCT02938078Not ApplicableTerminated

Ocular Comfort and Inflammation in Lid Hygiene Therapy

Role: collaborator

NCT02130518Phase 2Unknown

Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency

Role: lead

NCT01532336Phase 2Completed

Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis

Role: lead

NCT01877694Phase 2Completed

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

Role: lead

NCT02455895Not ApplicableUnknown

Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora

Role: lead

NCT01670032Phase 2Completed

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

Role: lead

NCT01243125Phase 2Completed

Study to Evaluate NVC-422 for Urinary Catheter Blockage and Encrustation

Role: lead

NCT00781339Phase 2Completed

Safety and Efficacy Study of NVC-422 on Bacteriuria in Catheterized Patients

Role: lead

NCT01367314Phase 2Completed

Safety and Efficacy of Topical NVC-422 Gel in Impetigo

Role: lead

All 10 trials loaded